Patient deaths reported in Tecentriq, Cotellic combo arm of mCRC trial
Roche (SIX:ROG; OTCQX:RHHBY) said it temporarily halted recruitment in the Phase II MODUL trial to treat metastatic colorectal cancer following four deaths, including a case of treatment-related cardiogenic shock, in a cohort of patients receiving Tecentriq atezolizumab in combination with Cotellic cobimetinib.
MODUL is evaluating combinations of anticancer agents as maintenance treatment of first-line mCRC in biomarker-selected populations following induction treatment with FOLFOX chemotherapy and Avastin bevacizumab. The cohort evaluating Tecentriq plus Cotellic enrolled HER2-negative, microsatellite instability-high (MSI-H) patients; HER2-negative, microsatellite-stable, wild-type BRAF patients; and HER2-negative, microsatellite-stable, BRAF-mutant, K-Ras (KRAS)-mutant patients...